Tags

Type your tag names separated by a space and hit enter

Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.
Metabolism. 2013 Jan; 62(1):121-6.M

Abstract

OBJECTIVE

Clinical data regarding Helicobacter pylori (Hp) infection in nonalcoholic fatty liver disease (NAFLD) are limited. The aim was the evaluation of Hp infection in patients with NAFLD and its association with disease severity.

METHODS

28 patients with biopsy-proven NAFLD (15 with simple nonalcoholic fatty liver [NAFL], 13 with nonalcoholic steatohepatitis [NASH]) and 25 matched healthy controls were recruited. Blood samples for anti-Hp Immunoglobulin G (IgG) and standard biochemical tests were obtained after overnight fasting, and (13)C urea breath test was performed before liver biopsy in NAFLD group.

RESULTS

Higher rates of anti-Hp IgG (P=.038) were observed in NAFLD compared to control group. Only two NAFLD patients neither were Hp IgG seropositive nor did they have a history of eradication treatment compared to 11 control subjects (P=.002). Both Hp infection (assessed by history of Hp eradication treatment and/or Hp IgG seropositivity) (P=.034) and log(HOMA-IR) (P=.007) could independently predict NAFLD in logistic regression analysis. There were similar rates of Hp IgG seropositivity or positivity in (13)C urea breath test or their combination between NAFL and NASH patients. There were no significant differences in steatosis grade, fibrosis stage, lobular or portal inflammation, or ballooning, when NAFLD patients were divided according to Hp IgG seropositivity or (13)C urea breath test positivity.

CONCLUSIONS

Hp infection may represent one more hit contributing to the pathogenesis of NAFL, though not to the progression from NAFL to NASH. These results warrant further validation. If confirmed, eradicating Hp infection may have certain therapeutic perspectives in NAFLD treatment.

Authors+Show Affiliations

Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece. stergios@endo.grNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22841522

Citation

Polyzos, Stergios A., et al. "Helicobacter Pylori Infection in Patients With Nonalcoholic Fatty Liver Disease." Metabolism: Clinical and Experimental, vol. 62, no. 1, 2013, pp. 121-6.
Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013;62(1):121-6.
Polyzos, S. A., Kountouras, J., Papatheodorou, A., Patsiaoura, K., Katsiki, E., Zafeiriadou, E., Zavos, C., Anastasiadou, K., & Terpos, E. (2013). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 62(1), 121-6. https://doi.org/10.1016/j.metabol.2012.06.007
Polyzos SA, et al. Helicobacter Pylori Infection in Patients With Nonalcoholic Fatty Liver Disease. Metabolism. 2013;62(1):121-6. PubMed PMID: 22841522.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. AU - Polyzos,Stergios A, AU - Kountouras,Jannis, AU - Papatheodorou,Athanasios, AU - Patsiaoura,Kalliopi, AU - Katsiki,Evangelia, AU - Zafeiriadou,Efthimia, AU - Zavos,Christos, AU - Anastasiadou,Kyriaki, AU - Terpos,Evangelos, Y1 - 2012/07/27/ PY - 2012/04/04/received PY - 2012/06/22/revised PY - 2012/06/22/accepted PY - 2012/7/31/entrez PY - 2012/7/31/pubmed PY - 2013/5/4/medline SP - 121 EP - 6 JF - Metabolism: clinical and experimental JO - Metabolism VL - 62 IS - 1 N2 - OBJECTIVE: Clinical data regarding Helicobacter pylori (Hp) infection in nonalcoholic fatty liver disease (NAFLD) are limited. The aim was the evaluation of Hp infection in patients with NAFLD and its association with disease severity. METHODS: 28 patients with biopsy-proven NAFLD (15 with simple nonalcoholic fatty liver [NAFL], 13 with nonalcoholic steatohepatitis [NASH]) and 25 matched healthy controls were recruited. Blood samples for anti-Hp Immunoglobulin G (IgG) and standard biochemical tests were obtained after overnight fasting, and (13)C urea breath test was performed before liver biopsy in NAFLD group. RESULTS: Higher rates of anti-Hp IgG (P=.038) were observed in NAFLD compared to control group. Only two NAFLD patients neither were Hp IgG seropositive nor did they have a history of eradication treatment compared to 11 control subjects (P=.002). Both Hp infection (assessed by history of Hp eradication treatment and/or Hp IgG seropositivity) (P=.034) and log(HOMA-IR) (P=.007) could independently predict NAFLD in logistic regression analysis. There were similar rates of Hp IgG seropositivity or positivity in (13)C urea breath test or their combination between NAFL and NASH patients. There were no significant differences in steatosis grade, fibrosis stage, lobular or portal inflammation, or ballooning, when NAFLD patients were divided according to Hp IgG seropositivity or (13)C urea breath test positivity. CONCLUSIONS: Hp infection may represent one more hit contributing to the pathogenesis of NAFL, though not to the progression from NAFL to NASH. These results warrant further validation. If confirmed, eradicating Hp infection may have certain therapeutic perspectives in NAFLD treatment. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/22841522/Helicobacter_pylori_infection_in_patients_with_nonalcoholic_fatty_liver_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(12)00236-3 DB - PRIME DP - Unbound Medicine ER -